Quality of life in diabetes mellitus and the International Classification of Functioning Disability and Health: a study of some aspects

O diabetes mellitus (DM) pode ter um efeito profundo na qualidade de vida dos pacientes e a Classificação Internacional de Funcionalidade, Incapacidade e Saúde (CIF) é um instrumento válido para verificar a influência dos componentes de saúde na qualidade de vida. O objetivo deste estudo, é apresentar a distribuição de freqüência das categorias das CIF do Core Set resumido para DM, com comprometimento grave em um grupo de pacientes com a qualidade de vida muito afetada pelo diabetes. Métodos: Foram estudados 38 pacientes diabéticos, 76,3 % com DM2 e 23,7 % com DM1, utilizando-se dados clínicos, informação de qualidade de vida associada ao diabetes do questionário AddQoL e incapacidade associada ao diabetes: categorias do Core Set resumido da CIF com comprometimento grave e completo, e categorias cuja informação era insuficiente para especificar a gravidade do comprometimento. Análise estatística: análise descritiva dos dados. Resultados: Categorias de funções corporais mais gravemente afetadas foram b130, b210, b530, b540, de estruturas corporais foram s220, s410, s740, de atividades/participação foram d240, d570 e de fatores ambientais foram e110, e115. As estruturas menos classificadas foram pâncreas (s550), globo ocular (s220) e sistema nervoso parassimpático (s150). Conclusão: No grupo estudado de diabéticos com complicações crônicas, controle metabólico inadequado e qualidade de vida muito afetada pela doença, a presença de incapacidade no cuidado pessoal e de barreiras ambientais, é sugestivo de que estes fatores possam contribuir para uma pior qualidade de vida, embora comprometimentos nas funções e estruturas corporais tenham sido os mais prevalentes.Diabetes mellitus (DM) can have a profound impact on the patients’ quality of life and the International Classification on Functioning, Disability and Health (ICF) is a valid tool to verify the influence of the health components on quality of life. Objective: The aim of this study is to present the frequency distribution of the ICF categories of the summarized Core Set for DM with severe involvement in a group of patients whose quality of life was deeply affected by DM. Methods: A total of 38 patients with DM were studied, of whom 76.3 % had DM2 and 23.7% had DM1, using the clinical data, information on the quality of life associated to DM from the AddQoL questionnaire and the disability associated to diabetes: categories of the summarized Core Set of the ICF with severe and complete involvement and categories of which information was insufficient to specify the severity of the involvement. Statistical analysis: The descriptive analysis of the data was performed. Results: The bodily function categories that were more severely affected were b130, b210, b530, b540; categories of body structures were s220, s410, s740; of activities/participation were d240, d570 and of environmental factors were e110, e115. The least classified structures were the pancreas (s550), ocular globe (s220) and parasympathetic nervous system (s150). Conclusion: In the studied group of patients with DM that presented chronic complications, inadequate metabolic control and quality of life that was deeply affected by the disease, the presence of disability in self-care and environmental barriers suggests that these factors can contribute to a worsening in the quality of life, although bodily function and structure involvements were the most prevalent ones

Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome : Insights from the LUNG SAFE study

Publisher Copyright: © 2020 The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.Background: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. Methods: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 ≥ 0.60 during hyperoxemia). Results: Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%) had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55-100 mmHg) patients (P = 0.47). Conclusions: Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained. No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort. Trial registration: LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073publishersversionPeer reviewe

Pituitary Apoplexy After a Single Dose of Long-Acting Octreotide

Pituitary apoplexy (PA) is a rare and potentially life-threatening syndrome resulting from an acute infarction or hemorrhage of the pituitary gland. Although the pathogenesis is not fully understood, some predisposing factors such as pituitary stimulation tests, diabetes mellitus, anticoagulant or antiplatelet aggregation therapy, head trauma, and high blood pressure may play a role in its pathophysiology. Octreotide is the mainstay of medical treatment for acromegaly. The majority of reported complications of octreotide therapy are gastrointestinal. We report the case of a 51-year-old acromegalic woman who developed pituitary apoplexy within the context of high blood pressure and a single dose of long-acting octreotide. Our data suggest that the combination of hypertension and octreotide therapy enhances the risk of pituitary apoplexy

Tumor misto de células germinativas da região hipotálamo-hipofisária apresentando-se como craniofaringioma: relato de caso e revisão da literatura

Craniopharyngiomas and germ cell tumors (GCT) may affect the pituitary-hypothalamic region during childhood. Although different in origin, their clinical and radiological features may be similar. In this article we present a 5-year-old girl with clinical and radiological findings (computer tomography calcification) that were initially considered as craniopharyngioma. However clinical outcome, blood and cerebral spinal fluid tumoral markers, and results from anatomopathology and immunohistochemistry disclosed a mixed GCT. This case report highlights that some clinical features and radiological findings of pituitary-hypothalamic tumors may be misdiagnosed as craniopharyngioma mainly when there is a mature teratoma with cartilaginous tissue differentiation.Craniofaringiomas e tumores mistos de células germinativas (TCG) podem acometer a região hipotálamo-hipofisária durante a infância. Embora tenham diferentes origens, as manifestações clínicas e achados radiológicos podem ser semelhantes. Nosso objetivo é relatar o caso de uma paciente de 5 anos de idade, cujas manifestações clínicas e achados radiológicos (presença de calcificações à tomografia computadorizada [TC]) foram inicialmente considerados como provável craniofaringioma. No entanto, a piora clínica progressiva, marcadores tumorais séricos e liquóricos elevados, assim como os resultados do estudo anatomopatológico e imunoistoquímico revelaram tratar-se de TCG. Este caso enfatiza que alguns achados clínicos e radiológicos de tumores da região hipotálamo-hipofisária podem ser erroneamente diagnosticados como craniofaringiomas, principalmente se houver presença de teratoma maduro com diferenciação em tecido cartilaginoso

Where Brain, Body and World Collide

The production cross section of electrons from semileptonic decays of beauty hadrons was measured at mid-rapidity (|y| &lt; 0.8) in the transverse momentum range 1 &lt; pt &lt; 8 Gev/c with the ALICE experiment at the CERN LHC in pp collisions at a center of mass energy sqrt{s} = 7 TeV using an integrated luminosity of 2.2 nb^{-1}. Electrons from beauty hadron decays were selected based on the displacement of the decay vertex from the collision vertex. A perturbative QCD calculation agrees with the measurement within uncertainties. The data were extrapolated to the full phase space to determine the total cross section for the production of beauty quark-antiquark pairs

Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients : data from South American registries BIOBADABRASIL and BIOBADASAR

Most reports on serious infections (SI) in rheumatoid arthritis (RA) patients treated with biological disease-modifying antirheumatic drugs (bDMARDs) are from the USA and Western Europe. Data from other regions are largely missing. We report data from South American countries with different backgrounds and health-care systems but similar registries. We merged 2010-2016 data from two registries, BIOBADABRASIL (Brazil) and BIOBADASAR (Argentina), which share the same protocol, online platform and data monitoring process. Patients with active RA were included when they began the first bDMARD or a conventional synthetic DMARD (csDMARD, control group). The SI incidence rate (IR) per 1000 patient/years and adjusted IR ratio (aIRR) were estimated for bDMARDs and csDMARDs. Data were analysed for 3717 RA patients with an exposure of 13,380 patient/years. The 2591 patients treated with bDMARDs (64% tumour necrosis factor-alpha inhibitors (TNFi)) had a follow-up of 9300years, and the 1126 treated with csDMARDs had an exposure of 4081 patient/years. The SI IR was 30.54 (CI 27.18-34.30) for all bDMARDs and 5.15 (CI 3.36-7.89) for csDMARDs. The aIRR between the two groups was 2.03 ([1.05, 3.9] p=0.034) for the first 6months of treatment but subsequently increased to 8.26 ([4.32, 15.76] p<0.001). The SI IR for bDMARDs decreased over time in both registries, dropping from 36.59 (28.41-47.12) in 2012 to 7.27 (4.79-11.05) in 2016. While SI remains a major concern in South American patients with RA treated with bDMARDs, a favourable trend toward a reduction was observed in the last years3882129213